Siemens Healthcare Partners with Pfizer to Develop Companion Diagnostics
|
By LabMedica International staff writers Posted on 11 Feb 2014 |
|
Siemens Healthcare Diagnostics, of Siemens Healthcare (Erlangen, Germany), has entered into a collaboration agreement with the global, research-based pharmaceutical company Pfizer (New York City, NY, USA), to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Electrolyte Analyzer
BKE-B
Latest Industry News
- FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
- CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
- Thermo Fisher Scientific to Sell Microbiology Business to Astorg
- Collaboration Expands Access to Rapid Metagenomic Diagnostics for Complex Infections
- Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
- QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
- QIAGEN Showcases Integrated Sample-to-Insight Oncology Solutions at AACR 2026
- Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
- Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
- Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
- Junction, GRAIL Enable Scalable Access to Multi-Cancer Detection Test
- GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
- Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
- Takara Bio USA and Hamilton Partner to Automate NGS Library Preparation
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
- Integrated DNA Technologies Expands into Clinical Diagnostics
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Molecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more
Immunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
